The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

The shingles vaccine is recommended for healthy adults age 50 or older, and also for anyone age 19 years or older who has a ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...

To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...